CubaPLUS Magazine

 The Cuban drug Jusvinza, initially developed to manage hyperinflammation and yielding positive outcomes in critically ill COVID-19 patients, is currently in Phase III clinical trials to evaluate its impact on other autoimmune diseases.

 Gillian Martínez Donato, the project manager, informed the press that this innovative molecule, which serves as an alternative treatment for patients with autoimmune disorders, especially rheumatoid arthritis, has shown additional potential in preclinical studies.

 Developed by the Center for Genetic Engineering and Biotechnology, Jusvinza is tailored to control hyperinflammation. The team is now focused on demonstrating its effectiveness in other autoimmune conditions such as ankylosing spondylitis, systemic lupus erythematosus, and inflammatory bowel diseases, with plans to advance to clinical trials thereafter.

 In the case of rheumatoid arthritis, clinical trials have shown that it improves the quality of life for patients with moderate conditions.

 "We also have evidence from real-world studies showing benefits in severe rheumatoid arthritis patients treated with Jusvinza," the scientist told Granma.

 She specified that a Phase III clinical trial is nearing completion, which will enable its widespread registration and use in Cuba, anticipated for next year.

 "This product is a therapeutic medication, not a preventive one. It's used in patients already diagnosed with autoimmune diseases," she emphasized.

 "Our goal in treating these autoimmune diseases is to achieve remission for patients," she noted.

 During the COVID-19 pandemic, Jusvinza was granted emergency use authorization for critical, severe, and moderate cases, preventing the progression to more advanced stages.

 Furthermore, the scientist added that Phase II-III clinical trials have started, employing blinded, randomized, and controlled methods, for acute respiratory distress syndrome due to various causes, including trauma or bacterial and viral infections.

 Another trial is also in progress for severe community-acquired pneumonia, for which Jusvinza has shown promise.

(Taken from Prensa Latina)